Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion.
Arata Y, Motoyama S, Yano M, Ikuno T, Ito S, Matsushita T, Takeiri A, Nishito Y, Yabuki N, Mizuno H, Sampei Z, Mishima M, Honda M, Kiyokawa J, Suzuki H, Chiba S, Tabo M, Kubo C.
Arata Y, et al. Among authors: kiyokawa j.
MAbs. 2023 Jan-Dec;15(1):2253570. doi: 10.1080/19420862.2023.2253570.
MAbs. 2023.
PMID: 37682072
Free PMC article.